Segment Data (Tables)

3 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Financial Information for Company's Segments

Financial information for the Company’s segments was as follows:

	Three Months Ended December 31,
(Millions of dollars)	2014			2013
Revenues (A)
Medical	$	1,072		$	1,064
Life Sciences		979			951
Total Revenues	$	2,051		$	2,015
Segment Operating Income
Medical	$	304		$	294
Life Sciences		214			234
Total Segment Operating Income		517			528
Unallocated Items (B)		(232	) (C)		(170	)
Income Before Income Taxes	$	285		$	359

(A) Intersegment revenues are not material.

(B) Includes primarily interest, net; foreign exchange; corporate expenses; share-based compensation expense; and acquisition-related costs.

(C) Includes $44 million of financing costs, as well as $23 million of integration and transaction costs, associated with the pending CareFusion acquisition. Additional disclosures regarding this pending acquisition are provided in Note 9. Also includes a $12 million charge for RTI’s attorneys’ fees associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit RTI filed against BD. For further discussion, refer to Note 5 in the notes to the financial statements.

Revenues by Geographic Areas

Revenues by geographic areas were as follows:

	Three Months Ended December 31,
(Millions of dollars)	2014		2013
Revenues
United States	$	881	$	849
International		1,170		1,166
Total Revenues	$	2,051	$	2,015